title: Antibody drug conjugates: lessons from 20 years of clinical experience.
abstract: Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.
authors.affiliation: South Texas Accelerated Research Therapeutics (START), San Antonio, USA atolcher@start.stoh.com.
authors.forename: A W
authors.initials: AW
authors.lastname: Tolcher
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D004364:Pharmaceutical Preparations
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D004364:Pharmaceutical Preparations
keywords: ADC; antibody drug conjugate